Question to the Department of Health and Social Care:

To ask Her Majesty's Government what measures they plan to take to protect immunocompromised, clinically extremely vulnerable people if research evidence demonstrates that COVID-19 vaccines are less effective for those people.

Treatments containing COVID-19 neutralising antibodies have been secured from AstraZeneca to support immunocompromised people who will not be able to benefit from a COVID-19 vaccine.  The antibody treatment currently being developed by AstraZeneca is a combination of two monoclonal antibodies and has the potential to be given as a preventative option for people exposed to the virus and to treat and prevent disease progression in patients already infected by the virus if successful.